Bristol-Myers Squibb BuSpar
FDA grants pediatric marketing exclusivity extension to BuSpar (buspirone) until Nov. 22. Exclusivity for the anxiety disorder treatment would have expired May 22. FDA issued a second tentative approval May 23 to four companies for generic versions of buspirone. BuSpar had sales of $568 mil. in 1999
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth